Nant Capital, LLC - Oct 22, 2024 Form 3 Insider Report for Panbela Therapeutics, Inc. (PBLA)

Role
10%+ Owner
Signature
/s/ Charles Kenworthy, Manager, Nant Capital LLC
Stock symbol
PBLA
Transactions as of
Oct 22, 2024
Transactions value $
$0
Form type
3
Date filed
10/29/2024, 07:38 PM
Previous filing
Feb 20, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PBLA 8% Senior Convertible Tranche A Note due 2025 Oct 22, 2024 Common Stock 7.7M $0.37 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The 8% Senior Convertible Tranche A Note (the "Note") was issued pursuant to that certain Note Purchase Agreement by and between the Issuer and Nant Capital, LLC ("Nant Capital") dated October 22, 2024 (the "Purchase Agreement"). Pursuant to the Purchase Agreement, Nant Capital shall purchase an additional 8% Senior Convertible Tranche B Note on or before November 15, 2024.
F2 Subject to an issuance limitation in the event of a voluntary conversion of the Note occurring prior to the maturity date that prohibits Nant Capital from converting the Note to the extent that after giving effect to the issuance of the Issuer's common stock after such conversion, Nant Capital (together with Nant Capital's affiliates, and any other person acting as a group together with Nant Capital or any of Nant Capital's affiliates) would beneficially own in excess of 33.33% of the shares of the Issuer's common stock outstanding.
F3 Note held by Nant Capital. Dr. Patrick Soon-Shiong owns all of the equity interests of Nant Capital and Dr. Soon-Shiong may be deemed to have beneficial ownership of the shares held by Nant Capital.